A Phase 4 interventional study of sirolimus and cyclosporine or tacrolimus in Skin Neoplasms and Kidney Transplantation, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 23 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-11.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 381 studies in Skin Neoplasms with a site in United States — 64 open to participants now, 98 under way, 7 of them phase 3. Skin Neoplasms · United States.
Among the 381 studies in Skin Neoplasms with a site in United States, this one is the 108th largest by enrollment of the 290 interventional ones that give a count, is one of 8 that started in 2005, is one of 11 in phase 4, and was the 33rd registered.
606 studies on the registry are indexed under Skin Neoplasms; 128 are open to participants now.
Browse Skin Neoplasms studies →64 of the 381 studies in Skin Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18+
Rutgers, The State University of New Jersey · Sites in United States
Ages 13+ · Healthy volunteers
University of Utah · Sites in United States
Ages 18–29 · Healthy volunteers
Marissa Lobl · Sites in United States
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 105 Skin Neoplasms studies recruiting now, 85 (81%) set no upper age limit and 9 (9%) stop at 75 or younger; 15 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
381 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 84 · Phase 2 115 · Phase 3 26 · Phase 4 11
First in 1977; this study’s year is marked. 8 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 86 is above the median of 55 across 410 interventional studies indexed under Skin Neoplasms.
Median enrollment 44 across the 290 interventional studies, 149 across the 80 observational. Of the 258 that completed or were terminated, 92 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
108 of 381 have an industry lead sponsor. The 10 most frequent:
This study is registered under Wyeth is now a wholly owned subsidiary of Pfizer, one of the names counted as Pfizer. Under that name alone:
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
Pfizer has 8 studies filed under Skin Neoplasms — fewer than ten, so there is no comparison to draw.
34 of the studies in Skin Neoplasms with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05608291Phase 3Regeneron PharmaceuticalsA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | 2027-01-15 |
| NCT06947928Phase 3TuHURA Biosciences, Inc.Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma | 2027-03-31 |
| NCT05634252Phase 3University of UtahUndergraduate Skin Cancer Prevention Trial | 2027-09-04 |
| NCT07931664The Center for Clinical and Cosmetic ResearchEvaluating Photodynamic Therapy Used to Treat Cutaneous Squamous Cell Carcinoma in Situ (isSCC) on the Face, Upper Extremities & Trunk. | 2026-11 |
| NCT07201376Dartmouth-Hitchcock Medical CenterAssessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically | 2026-11 |
Add all 34 to your calendar (.ics) → With an account.
Among the 381 studies in Skin Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the effect of sirolimus on the prevention of new non-melanoma skin cancer (NMSC) in kidney transplant recipients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Conversion to a sirolimus-based regimen
Drug: sirolimus
Continuation of a CNI-based regimen
Drug: cyclosporine or tacrolimus
Drug pages: Cyclosporine · Tacrolimus
New Biopsy-Confirmed Nonmelanoma Skin Cancer (NMSC) Lesions Per Subject Per Year
The number of new biopsy-confirmed NMSC lesions per subject per year was calculated by summarizing the total number of new BCC and SCC lesions reported over the observation period and standardizing it to an annual rate by multiplying by 365 and dividing by days on study.
Time frame: up to 24 months
Time to First Biopsy Confirmed New NMSC Lesion.
The time to first biopsy confirmed new NMSC lesion starts at 1 day post randomization to biopsy and/or treatment of newly confirmed NMSC lesion.
Time frame: up to 24 months
Number of Lesion Free Subjects
The overall number of subjects who were lesion free were compared between treatment groups with the Cochran Mantel Haenszel test stratified by baseline NMSC stratum. Within each stratum, the Fisher exact test was used to compare the proportions of lesion free subjects between treatment groups.
Time frame: up to 24 months
Percentage of Patients With New Biopsy-confirmed NMSC: Squamous Cell Carcinoma (SCC) and Basal Cell Carcinoma (BCC)
Time frame: up to 24 months
Grade Distribution of NMSC Lesions
Number of subjects with at least 1 biopsy-confirmed new squamous cell carcinoma (SCC) or basal cell carcinoma (BCC).
Time frame: up to 24 months
Number of Recurrent NMSC Lesions Per Subject-year
Recurrent NMSC lesions is defined as recurring at the site of a previously treated lesion.
Time frame: up to 24 months
Subjects Reporting Incidence of Metastatic Disease Related to NMSC.
The number of subjects with metastatic disease related to NMSC.
Time frame: up to 24 months
Death Due to NMSC
Time frame: up to 24 months
Number of Subjects Who Discontinue Assigned Therapy
Time frame: up to 24 months
Nankivell-Calculated Glomerular Filtration Rate (GFR)
GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. For this study, GFR was calculated using Nankivell. A normal GFR is \> 90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poor kidney function. A GFR \<15 is consistent with kidney failure.
Time frame: At 24 months (week 104)
Serum Creatinine Level
Serum creatinine is an indicator of kidney function. Creatinine is a substance formed from the metabolism of creatinine, commonly found in blood, urine, and muscle tissue. It is removed from the blood by the kidneys and excreted in urine. An increased level of creatinine in the blood indicates decreased kidney function. Normal adult blood levels of creatinine are 0.5 to 1.1 mg/dL for females and 0.6 to 1.2 mg/dL for males, however the normal values are age-dependent as elderly patients typically have smaller muscle mass.
Time frame: At 24 months (Week 104)
Number of Participants That Died
Time frame: up to 24 months
Graft Survival Measured by Graft Loss
Graft loss was defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for \>8 consecutive weeks), retransplant, or death.
Time frame: up to 24 months
Number of Subjects With Biopsy-Confirmed Acute Rejection
Time frame: up to 24 months
Spot Urine Protein:Creatinine Ratio
Subjects' urine protein:creatinine ratios were summarized by each scheduled visit, and the nonparametric Wilcoxon rank sum test was used to compare the difference between groups.
Time frame: At 24 months (Week 104)
Subjects were recruited in Australia, New Zealand and North America from August 2005 (first subject randomized September 2005) through October 2007.
| Milestone | Sirolimus (SRL) Based Regimen | Calcineurin Inhibitor (CNI) Based Regimen |
|---|---|---|
| Started | 39 | 47 |
| Completed | 20 | 24 |
| Not completed | 19 | 23 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Withdrawal by sponsor | 14 | 20 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Missing record | 0 | 1 |
The number of new biopsy-confirmed NMSC lesions per subject per year was calculated by summarizing the total number of new BCC and SCC lesions reported over the observation period and standardizing it to an annual rate by multiplying by 365 and dividing by days on study.
| Standardized Yearly Rate of NMSC | Sirolimus (SRL) Based Regimen | Calcineurin Inhibitor (CNI) Based Regimen |
|---|---|---|
| New Biopsy-Confirmed Nonmelanoma Skin Cancer (NMSC) Lesions Per Subject Per Year | 1.31 ± 0.52 | 2.48 ± 0.69 |
The time to first biopsy confirmed new NMSC lesion starts at 1 day post randomization to biopsy and/or treatment of newly confirmed NMSC lesion.
| number of days | Sirolimus (SRL) Based Regimen | Calcineurin Inhibitor (CNI) Based Regimen |
|---|---|---|
| Time to First Biopsy Confirmed New NMSC Lesion. | 380 ± 42.42 | 163 ± 42.32 |
The overall number of subjects who were lesion free were compared between treatment groups with the Cochran Mantel Haenszel test stratified by baseline NMSC stratum. Within each stratum, the Fisher exact test was used to compare the proportions of lesion free subjects between treatment groups.
| participants | Sirolimus (SRL) Based Regimen | Calcineurin Inhibitor (CNI) Based Regimen |
|---|---|---|
| Number of Lesion Free Subjects | 17 | 9 |
| Percentage of Participants | Sirolimus (SRL) Based Regimen | Calcineurin Inhibitor (CNI) Based Regimen |
|---|---|---|
| SCC | 67 | 69 |
| BCC | 33 | 31 |
Number of subjects with at least 1 biopsy-confirmed new squamous cell carcinoma (SCC) or basal cell carcinoma (BCC).
| participants | Sirolimus (SRL) Based Regimen | Calcineurin Inhibitor (CNI) Based Regimen |
|---|---|---|
| SCC Well differentiated | 5 | 17 |
| SCC Moderately differentiated | 9 | 14 |
| SCC Poorly differentiated | 1 | 1 |
| SCC Invasive | 10 | 24 |
| SCC In Situ | 12 | 27 |
| SCC Invasive with Perineural Invasion | 2 | 1 |
| SCC Invasive without Perineural Invasion | 8 | 24 |
| BCC Superficial | 7 | 16 |
| BCC Nodular | 11 | 15 |
| BCC Infiltrative | 2 | 6 |
Recurrent NMSC lesions is defined as recurring at the site of a previously treated lesion.
| lesions per participant year | Sirolimus (SRL) Based Regimen | Calcineurin Inhibitor (CNI) Based Regimen |
|---|---|---|
| Number of Recurrent NMSC Lesions Per Subject-year | 0.107 ± 0.09 | 0.134 ± 0.10 |
The number of subjects with metastatic disease related to NMSC.
| participants | Sirolimus (SRL) Based Regimen | Calcineurin Inhibitor (CNI) Based Regimen |
|---|---|---|
| Subjects Reporting Incidence of Metastatic Disease Related to NMSC. | 1 | 3 |
| participants | Sirolimus (SRL) Based Regimen | Calcineurin Inhibitor (CNI) Based Regimen |
|---|---|---|
| Death Due to NMSC | 0 | 0 |
| participants | Sirolimus (SRL) Based Regimen | Calcineurin Inhibitor (CNI) Based Regimen |
|---|---|---|
| Number of Subjects Who Discontinue Assigned Therapy | 31 | 23 |
GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. For this study, GFR was calculated using Nankivell. A normal GFR is \> 90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poor kidney function. A GFR \<15 is consistent with kidney failure.
| units on scale | Sirolimus (SRL) Based Regimen | Calcineurin Inhibitor (CNI) Based Regimen |
|---|---|---|
| Nankivell-Calculated Glomerular Filtration Rate (GFR) | 72.49 ± 24.41 | 68.42 ± 19.91 |
Serum creatinine is an indicator of kidney function. Creatinine is a substance formed from the metabolism of creatinine, commonly found in blood, urine, and muscle tissue. It is removed from the blood by the kidneys and excreted in urine. An increased level of creatinine in the blood indicates decreased kidney function. Normal adult blood levels of creatinine are 0.5 to 1.1 mg/dL for females and 0.6 to 1.2 mg/dL for males, however the normal values are age-dependent as elderly patients typically have smaller muscle mass.
| μmol/L | Sirolimus (SRL) Based Regimen | Calcineurin Inhibitor (CNI) Based Regimen |
|---|---|---|
| Serum Creatinine Level | 139.35 ± 41.63 | 135.23 ± 37.84 |
| participants | Sirolimus (SRL) Based Regimen | Calcineurin Inhibitor (CNI) Based Regimen |
|---|---|---|
| Number of Participants That Died | 1 | 1 |
Graft loss was defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for \>8 consecutive weeks), retransplant, or death.
| graft loss | Sirolimus (SRL) Based Regimen | Calcineurin Inhibitor (CNI) Based Regimen |
|---|---|---|
| Graft Survival Measured by Graft Loss | 2 | 1 |
| subjects | Sirolimus (SRL) Based Regimen | Calcineurin Inhibitor (CNI) Based Regimen |
|---|---|---|
| Number of Subjects With Biopsy-Confirmed Acute Rejection | 0 | 1 |
Subjects' urine protein:creatinine ratios were summarized by each scheduled visit, and the nonparametric Wilcoxon rank sum test was used to compare the difference between groups.
| ratio (mg/mg) | Sirolimus (SRL) Based Regimen | Calcineurin Inhibitor (CNI) Based Regimen |
|---|---|---|
| Spot Urine Protein:Creatinine Ratio | 0.14 ± 0.28 | 0.12 ± 0.08 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sirolimus (SRL) Based Regimen | — | 15/39 (38.5%) | 38/39 (97.4%) |
| Calcineurin Inhibitor (CNI) Based Regimen | — | 21/47 (44.7%) | 40/47 (85.1%) |
| Event | Sirolimus (SRL) Based Regimen | Calcineurin Inhibitor (CNI) Based Regimen |
|---|---|---|
| PneumoniaRespiratory, thoracic and mediastinal disorders | 3/39 | 2/47 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 3/39 | 0/47 |
| SepsisGeneral disorders | 0/39 | 3/47 |
| GastroenteritisGastrointestinal disorders | 1/39 | 3/47 |
| Prostatic carcinomaRenal and urinary disorders | 2/39 | 1/47 |
| Rectal hemorrhageGastrointestinal disorders | 0/39 | 2/47 |
| Skin carcinomaSkin and subcutaneous tissue disorders | 1/39 | 2/47 |
| Skin melanomaSkin and subcutaneous tissue disorders | 0/39 | 2/47 |
| Urinary tract infectionRenal and urinary disorders | 1/39 | 2/47 |
| Allergic reactionGeneral disorders | 1/39 | 0/47 |
| Event | Sirolimus (SRL) Based Regimen | Calcineurin Inhibitor (CNI) Based Regimen |
|---|---|---|
| DiarrheaGastrointestinal disorders | 16/39 | 6/47 |
| Peripheral edemaMetabolism and nutrition disorders | 16/39 | 3/47 |
| Mouth ulcerationGastrointestinal disorders | 13/39 | 0/47 |
| RashSkin and subcutaneous tissue disorders | 13/39 | 1/47 |
| Cough increasedRespiratory, thoracic and mediastinal disorders | 8/39 | 6/47 |
| AcneSkin and subcutaneous tissue disorders | 7/39 | 1/47 |
| AlbuminuriaRenal and urinary disorders | 7/39 | 0/47 |
| PainGeneral disorders | 6/39 | 5/47 |
| HypertensionCardiac disorders | 6/39 | 4/47 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 6/39 | 0/47 |
| Age Continuous(years) | Sirolimus (SRL) Based Regimen | Calcineurin Inhibitor (CNI) Based Regimen | Total |
|---|---|---|---|
| Mean | 59.08 (36 to 76) | 58.98 (37 to 78) | 59.02 (36 to 78) |
| Sex: Female, Male(Participants) | Sirolimus (SRL) Based Regimen | Calcineurin Inhibitor (CNI) Based Regimen | Total |
|---|---|---|---|
| Female | 8 | 13 | 21 |
| Male | 31 | 34 | 65 |
| Stratification Group(subjects) | Sirolimus (SRL) Based Regimen | Calcineurin Inhibitor (CNI) Based Regimen | Total |
|---|---|---|---|
| 0-5 Lesions in 12 months prior | 33 | 39 | 72 |
| 6-20 Lesions in 12 months prior | 6 | 8 | 14 |
| Time from Current Transplantation to Randomization(Months) | Sirolimus (SRL) Based Regimen | Calcineurin Inhibitor (CNI) Based Regimen | Total |
|---|---|---|---|
| Mean | 114.98 ± 57.63 | 109.57 ± 55.08 | 112.02 ± 55.98 |
The record gives a start of Aug 2005, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 3 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sirolimus
Wyeth is now a wholly owned subsidiary of Pfizer →